Sprazole-20/Sprazole-40

Esomeprazole Mg trihydrate

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Erosive reflux esophagitis; long-term management of patients w/ healed esophagitis (relapse prevention); symptomatic treatment of GERD. In combination w/ appropriate antibacterial therapeutic regimen for H. pylori eradication & healing of H. pylori-associated duodenal ulcers, & prevention of peptic ulcer relapse in patients w/ H. pylori-associated ulcers. Patients requiring continued NSAID therapy for healing of gastric ulcers associated w/ NSAID therapy; prevention of gastric & duodenal ulcers associated w/ NSAID therapy in patients at risk (≥60 yr &/or w/ documented history of gastric &/or duodenal ulcers). Prevention of gastric &/or duodenal ulcers associated w/ low dose ASA therapy in patients at risk. Prevention of gastric or duodenal ulcer rebleeding following treatment w/ esomeprazole IV soln by IV infusion. Zollinger-Ellison syndrome.

Adult & adolescent ≥12 yr Erosive reflux esophagitis 40 mg once daily for 4 wk. Additional 4 wk treatment is recommended for patients in whom esophagitis has not healed or who have persistent symptoms. Long-term management of patients w/ healed esophagitis to prevent relapse 20 mg once daily. Symptomatic treatment of GERD 20 mg once daily in patients w/o esophagitis. Once symptoms have resolved, may take 20 mg once daily when needed for subsequent symptom control. Adult In combination w/ an appropriate antibacterial therapeutic regimen for H. pylori eradication & healing of H. pylori-associated duodenal ulcers, & prevention of peptic ulcer relapse in patient w/ H. pylori-associated ulcers 20 mg w/ amoxicillin 1 g & clarithromycin 500 mg, all bd for 7 days. Healing of gastric ulcers associated w/ NSAID therapy 20 mg once daily for 4-8 wk. Prevention of gastric & duodenal ulcers associated w/ NSAID therapy in patient at risk 20 mg once daily. Prevention of gastric &/or duodenal ulcers associated w/ low dose ASA therapy in patient at risk 20 or 40 mg once daily. Prevention of gastric or duodenal ulcer rebleeding following treatment w/ esomeprazole IV soln by IV infusion 40 mg once daily for 4 wk after IV. Zollinger-Ellison syndrome Initially 40 mg bd. May be individually adjusted & continued as long as clinically indicated. Doses >80 mg daily should be divided & given bd. Severe hepatic impairment Max: 20 mg daily.

May be taken with or without food: Swallow whole, do not chew/crush. For patients w/ swallowing difficulties, disperse tab in a ½ glass of non-carbonated water. No other liqd should be used. Stir gently until the tab dissolves into little pellets & drink the liqd w/ the pellets immediately or w/in 30 min. Rinse the glass w/ ½ glass of water & drink. The dispersion may also be administered via gastric tube.

Hypersensitivity to esomeprazole & substituted benzimidazoles.

Antacids, Antireflux Agents & Antiulcerants

A02BC05 - esomeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).

POM